Area of research
Genetics · Biophysics
Research interest
Research interests include Biology, Medicine, Temozolomide, Internal medicine, Cancer research, and Clinical endpoint.
Programs, origins and immunomodulatory functions of myeloid cells in glioma
Cross-species comparison reveals therapeutic vulnerabilities halting glioblastoma progression
Autism-associated CHD8 controls reactive gliosis and neuroinflammation via remodeling chromatin in astrocytes
Somatic instability of the <i>FGF14</i> -SCA27B GAA•TTC repeat reveals a marked expansion bias in the cerebellum
Somatic instability of the <i>FGF14</i> -SCA27B GAA•TTC repeat reveals a marked expansion bias in the cerebellum
Single-cell spatial immune landscapes of primary and metastatic brain tumours
Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated <i>MGMT</i> promoter
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma
Spatially mapping the immune landscape of melanoma using imaging mass cytometry
Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles
CTIM-25. A RANDOMIZED PHASE 3 STUDY OF NIVOLUMAB OR PLACEBO COMBINED WITH RADIOTHERAPY PLUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA WITH METHYLATED MGMT PROMOTER: CHECKMATE 548
Single-cell RNA-seq reveals that glioblastoma recapitulates a normal neurodevelopmental hierarchy
MAFG-driven astrocytes promote CNS inflammation
Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma
MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence
LTBK-08. TOCA 511 & TOCA FC VERSUS STANDARD OF CARE IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma
Preclinical target validation using patient-derived cells